Avacta Group (AVCT) Given “Corporate” Rating at FinnCap
FinnCap reaffirmed their corporate rating on shares of Avacta Group (LON:AVCT) in a report published on Monday morning. FinnCap currently has a GBX 200 ($2.71) price target on the biotechnology company’s stock.
Avacta Group (LON:AVCT) opened at GBX 66.50 ($0.90) on Monday. The firm has a market cap of $45.90 and a price-to-earnings ratio of -738.89. Avacta Group has a 52-week low of GBX 60 ($0.81) and a 52-week high of GBX 98 ($1.33).
Avacta Group Company Profile
Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.